Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
Do you start prostate radiotherapy sooner in patients receiving neoadjuvant GnRH antagonists relugolix versus agonists such as leuprolide?
Related Questions
Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?
Is there a role for prostate cancer lesion boost with EBRT in the setting of combination EBRT+ brachytherapy?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
Would you offer salvage radiation for a local recurrence of prostate cancer that was initially treated with SBRT?
Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?
How would you treat high risk prostate cancer in a patient with autonomic bladder dysfunction?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?
